Cancer vaccines: What do we need to measure in clinical trials?

被引:8
|
作者
Kudrin, Alex [1 ]
机构
[1] Celltrion Inc, Inchon, South Korea
关键词
cancer vaccines; endpoints; immune response; patient reported outcomes; progression free survival; SIPULEUCEL-T; IMMUNOTHERAPY; SURVIVAL; APPROVAL; THERAPY;
D O I
10.4161/hv.27586
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is dedicated to evaluate remaining challenges in capturing clinical response with cancer vaccines. Definition of disease progression in context of clinical rather image-specific criteria and interpretation of efficacy in relation to delayed effect of cancer vaccines should be taken into account in the design of future of immunotherapy trials.
引用
收藏
页码:3236 / 3240
页数:5
相关论文
共 50 条